Downregulation of miR‑1266‑5P, miR‑185‑5P and miR‑30c‑2 in prostatic cancer tissue and cell lines

Abstract

Over the latest decade, the role of microRNAs (miRNAs/miRs) has received more attention. miRNAs are small non-coding RNAs that may serve a role as oncogenes or tumor suppressor genes. Certain miRNAs regulate the apoptosis pathway by influencing pro- or anti-apoptotic genes. We hypothesized that increases in the expression of B cell lymphoma 2 () and BCL2-like 1 () genes, which have been reported in various types of cancer tissues, may be due to the downregulation of certain miRNAs. The present study aimed to identify miRNAs that target and anti-apoptotic genes in prostate cancer (PCa) clinical tissue samples. Certain candidate miRNAs were selected bioinformatically and their expression in PCa samples was analyzed and compared with that in benign prostatic hyperplasia (BPH) tissue samples. The candidate miRNAs that targeted and genes were searched in online databases (miRWalk, microRNA.org, miRDB and TargetScan). A total of 12 miRNAs that target the 3'-untranslated region of the aforementioned genes and/or for which downregulation of their expression has previously been reported in cancer tissues. A total of 30 tumor tissue samples from patients with PCa and 30 samples tissues from patients with BPH were obtained and were subjected to reverse transcription-quantitative polymerase chain reaction for expression analysis of 12 candidate miRNAs, and the and genes. Additionally, expression of 3 finally selected miRNAs and genes was evaluated in prostate cancer PC3 and DU145 cell lines and human umbilical vein endothelial cells. Among 12 miRNA candidates, the expression of miR-1266, miR-185 and miR-30c-2 was markedly downregulated in PCa tumor tissues and cell lines. Furthermore, downregulation of these miRNAs was associated with upregulation of the and genes. An inverse association between three miRNAs (miR-1266, miR-185 and miR-30c-2) and two anti-apoptotic genes ( and ) may be considered for interventional miRNA therapy of PCa.

Small Non-Coding RNA Profiling in Plasma Extracellular Vesicles of Bladder Cancer Patients by Next-Generation Sequencing: Expression Levels of miR-126-3p and piR-5936 Increase with Higher Histologic Grades

“…In our study, low expression levels of miR-185-5p and miR-106a-5p or the high expression of miR-10b-5p were associated with a short survival. miR-185-5p has been already reported in the literature as a potential cancer biomarker for melanoma [38], prostate [39], and bladder cancer [14,40]. However, the expression rates of this miRNA are not consistent across studies, thus raising some issues about the possibility to clarify its complex molecular involvement in tumor progression, also considering the heterogeneity of tissues and cancer types.…”

microRNAs Orchestrate Pathophysiology of Breast Cancer Brain Metastasis: Advances in Therapy

“…Some of them were validated in BM, such as TWIST1, GSTA5, and BCL2L1 [106]. Interestingly, BCL2L1 is regulated by miR-1266, miR-185, and miR-30c [60] in prostate cancer. TWIST1 is regulated by miR-151-3p in BC [61].…”

<p>Knockdown of lncRNA <em>PCAT6</em> Enhances Radiosensitivity in Triple-Negative Breast Cancer Cells by Regulating<em> miR-185-5p</em>/<em>TPD52</em> Axis</p>

“…18 At present, emerging evidence revealed that miRNAs could affect cellular responses to radiation and modulate the radiosensitivity of many cancers. 19 MiR-185-5p has been suggested to be dysregulated in many kinds of cancers, such as prostatic cancer, 20 hepatocellular carcinoma, 21 clear cell renal cell carcinoma. 22 Moreover, previous study suggested that miR-185-5p was expressed at a low level in BC cells.…”